| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cadre Holdings, Inc.
$32.82
-2.2 (-6.28%)
Market Cap
1.40 B
EPS
1.08
P/E Ratio
30.39 $
Value Trade
11.57 M
SEC Financials
Q2 2026Dilution Risk
Revenue
207.13 M
Total Assets
917.30 M
Total Liabilities
570.50 M
Equity
346.80 M
6.39 %
Week
15.85 %
1 Month
4.66 %
3 Month
-22.69 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
57.67 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
Aug 5, 2026
Overview
Volume
472.30 K
52 Week Range
25.73 - 48.76
% held by Insiders
27.58 %
% held by Institutions
77.59 %
Enterprise Value
1.72 B
Total Shares
42.79 M
Short %
8.73 %
Float Shares
29.91 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CDRE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CDRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CDRE
Aug 10, 2026▼ -6.3%today
Seegene propose une approche globale de dépistage des infections de l'appareil génital dans le cadre de la Global Million Clinical Study (GMCS)
Seegene Inc. has proposed a comprehensive syndromic screening approach for genital infections as part of the Global Million Clinical Study (GMCS). The study, which analyzed around 60,000 results over 42 months, found that pathogens responsible for STIs were detected in 82% of HPV positive cases. This initiative aims to validate the clinical utility of combined HPV and STI screening and establish a new global standard for PCR testing.
Read more →-CDRE
Jun 17, 2026VahatiCor recrute son premier patient américain dans le cadre de l'étude clinique SERRA-I portant sur le système A-FLUX Reducer System® pour le traitement de la CMD
VahatiCor has successfully recruited its first American patient for the SERRA-I clinical study, evaluating the A-FLUX Reducer System for treating coronary microvascular dysfunction (CMD). This milestone follows initial human results and ongoing recruitment in Europe. The study aims to provide crucial data for patients suffering from CMD, a condition with limited treatment options.
Read more →-CDRE
Jun 12, 2026Inventiva annonce le Remboursement des Prêts BEI, le Rachat d'une partie des BSA BEI et l'émission des deux premières tranches dans le cadre du Nouveau Financement
Inventiva has successfully completed the repayment of existing BEI loans amounting to approximately €62 million and has repurchased all existing BEI warrants. Additionally, the company issued two tranches of bonds, raising a total of €75 million, as part of its financing operation managed by BlackRock and Claret Capital Partners. These steps follow the closure of a previously announced equity offering.
Read more →-CDRE
May 11, 2026▲ +5.1%on this news
Cadre Holdings Reports First Quarter 2026 Financial Results Q1 Net Sales Grew 19% Year-Over-Year Record Orders Backlog of $355 Million; Organic Backlog Increased $108 Million from Q4 to Q1 Reaffirms 2026 Full-Year Guidan
Cadre Holdings reported a strong first quarter for 2026, with net sales growing by 19% year-over-year to $155.4 million. They achieved a record orders backlog of $355 million, bolstered by recent acquisitions and heightened demand in safety equipment. However, net income fell to $2 million, marking a significant decrease compared to the previous year's quarter. Despite these challenges, the company reaffirmed its full-year guidance, reflecting confidence in its growth trajectory and strategic positioning in the market.
Read more →-CDRE
Mar 10, 2026▼ -7.5%on this news· ran to -28% by day 3
Cadre Holdings Reports Fourth Quarter and Full Year 2025 Financial Results Generated Annual Net Sales of $610.3 Million, Gross Margin of 42.5% and Net Income of $44.1 Million Achieved Record Annual Adjusted EBITDA for Th
Cadre Holdings announced its fourth quarter and full year 2025 financial results, reporting net sales of $610.3 million and a gross margin of 42.5%. The company achieved record adjusted EBITDA for the third consecutive year and anticipates further growth in 2026, with projected net sales of $736 to $758 million. However, there was a decline in net income and gross profit margin for the fourth quarter, attributed to previous high shipment levels and rising costs. The company remains focused on acquisitions to enhance its market leadership in safety products.
Read more →-CDRE
Nov 4, 2025Cadre Holdings Reports Third Quarter 2025 Financial Results Grew Quarterly Net Sales 42% and Gross Profit 66% Year-Over-Year Increased Quarterly Adjusted EBITDA of $29.8 Million and Expanded Adjusted EBITDA Margin of 19.
Cadre Holdings has reported strong financial results for the third quarter of 2025, with net sales rising by 42% and gross profit climbing by 66% year-over-year. Adjusted EBITDA also increased significantly to $29.8 million, reflecting the company's growth strategy, including a recent acquisition of TYR Tactical. The firm reported a marked improvement in backlog and profitability, although higher administrative expenses and increased compensation costs have posed challenges. As Cadre looks to broaden its market presence, it remains focused on pursuing further acquisitions and leveraging strong demand in its core markets.
Read more →-CDRE
Oct 29, 2025ACQUISITION OVERVIEW
Cadre has announced the acquisition of TYR Tactical for a total consideration of $175 million, which includes $150 million in cash and $25 million in stock. This strategic move is designed to capitalize on new growth opportunities in high-value markets such as European military and defense sectors. The acquisition aims to provide significant operational synergies and further strengthen Cadre's position in the tactical gear market. However, there are risks associated with the completion of this acquisition and the integration process that could impact the company's future performance.
Read more →-CDRE
Oct 8, 2025INVESTOR DAY
Cadre Nuclear Group showcased its strategic initiatives aimed at supporting the nuclear energy sector during an investor day. Key highlights included a focus on environmental management, national security, and the company's commitment to enhancing nuclear safety and operations. The organization emphasized its rapid growth potential through recent acquisitions and investments, which position it favorably in an evolving market influenced by demand for reliable energy sources. Upcoming projects are expected to capitalize on government mandates and private investments supporting nuclear technologies.
Read more →-CDRE
Aug 5, 2025Cadre Holdings Reports Second Quarter 2025 Financial Results Increased Quarterly Net Sales 9% and Gross Profit 10% Year-Over-Year Continued Strong Demand Trends for Mission Critical Safety Equipment
Cadre Holdings, Inc. reported a strong performance in the second quarter of 2025, with net sales and gross profit rising by 9% and 10% year-over-year, respectively. The company highlighted robust demand for its safety equipment across multiple markets, including law enforcement and nuclear safety sectors. Despite a slight decline in net income due to acquisition costs, the outlook remains positive driven by strategic acquisitions and a solid financial position. Cadre anticipates revenue growth due to increasing environmental and defense-related demands, although new tariffs may impact operations.
Read more →-CDRE
May 6, 2025Cadre Holdings Reports First Quarter 2025 Financial Results Capitalizes on Continued Strong Demand for Mission Critical Safety Equipment Completes Acquisition of Multiple Leading Nuclear Brands, Expanding Geographic Foot
Cadre Holdings, Inc. reported its first-quarter financial results for 2025, highlighting strong demand for its safety equipment. The company generated net sales of $130.1 million, showing resilience despite timing issues with large orders. The acquisition of Carr's Engineering Division is set to enhance Cadre's capabilities in the nuclear safety sector. Forward guidance indicates optimism, with anticipated net sales between $618 million and $648 million for the year.
Read more →-CDRE
Mar 11, 2025Cadre Holdings Reports Fourth Quarter and Full Year 2024 Financial Results Achieved Annual Net Sales of $568 Million, Gross Margin of 41.1% and Net Income of $36 Million Generated Record Annual Adjusted EBITDA and Adjust
Cadre Holdings reported strong financial results for the fourth quarter and full year of 2024, achieving net sales of $568 million and a gross margin of 41.1%. The company experienced notable net income of $36 million, although it faced rising selling and administrative expenses. Looking ahead, Cadre expects to generate net sales between $572 million and $601 million in 2025, propelled by recent acquisitions and ongoing positive demand in their product segments. CEO Warren Kanders highlighted the company's commitment to public safety and their strategic growth approach in nuclear safety markets.
Read more →-CDRE
Jan 16, 2025Acquisition Overview: Carr's Engineering Division
Cadre Holdings, Inc. announced the acquisition of Carr's Engineering division for an enterprise value of $75 million, aimed at enhancing its position in the nuclear market. This strategic move will allow Cadre to expand its offerings into new areas, including nuclear medicine. The acquisition is subject to regulatory approval and is expected to close in the first half of 2025. The deal is anticipated to strengthen Cadre's relationships with international customers and broaden its geographic and product footprint. However, there are risks related to the completion of the transaction and potential impacts on share prices.
Read more →-CDRE
Nov 6, 2024▲ +5.1%on this news
Cadre Holdings Reports Third Quarter 2024 Financial Results Favorable Market Trends Continue to Drive Strong Demand for Cadre's Mission Critical Safety Equipment
Cadre Holdings, Inc. reported its third quarter 2024 financial results, showcasing a solid demand for its safety equipment despite facing challenges from cybersecurity incidents. For the quarter, net sales reached $109.4 million, a decrease from the previous year, attributed to interruptions caused by cybersecurity threats. However, the company reported overall growth for the nine-month period, driven by recent acquisitions and strong demand for armor products. Cadre's management expressed confidence in the company's future, highlighting its innovative product offerings and plans for strategic growth.
Read more →-CDRE
Aug 9, 2024Cadre Holdings Reports Second Quarter 2024 Financial Results Grew Quarterly Net Sales 19% and Net Income 14% Year-Over-Year Increased Quarterly Adjusted EBITDA of $28.3 Million and Adjusted EBITDA Margin of 19.6%
Cadre Holdings reported strong financial results for Q2 2024, with net sales growing by 19% and net income by 14% year-over-year. The company's Adjusted EBITDA reached $28.3 million with a margin of 19.6%. Despite the positive results, a cyber incident occurred in July that temporarily limited production capacity, leading to revised sales forecasts for the year. Nevertheless, Cadre remains optimistic about long-term growth opportunities and is actively pursuing potential acquisitions.
Read more →-CDRE
May 7, 2024Cadre Holdings Reports First Quarter 2024 Financial Results Achieves Record Quarterly Net Sales of $137.9 Million and Gross Profit of $57.6 Million Reaffirms 2024 Full-Year Guidance
Cadre Holdings, Inc. reported a record quarterly net sales of $137.9 million for Q1 2024, marked by a 23% growth from the previous year. The gross profit also increased to $57.6 million, demonstrating improved margins. The company reaffirmed its full-year financial guidance, citing strong demand for its safety equipment and ongoing acquisitions, including ICOR Technology and Alpha Safety, to broaden its market presence. However, a minor dip in net income was attributed to increased administrative expenses following these acquisitions.
Read more →-CDRE
Mar 5, 2024Cadre Holdings Reports Fourth Quarter and Full Year 2023 Financial Results Achieved Annual Net Sales of $483 Million, Gross Margin of 41.6% and Net Income of $39 million Generated Record Annual Adjusted EBITDA and Adjust
Cadre Holdings, Inc. reported impressive financial results for the fourth quarter and full year of 2023, achieving record annual net sales of $483 million and a gross margin of 41.6%. The company anticipates continued growth in 2024, with projected net sales between $553 and $572 million. Strategic acquisitions of ICOR Technology and Alpha Safety are expected to enhance its product offerings, although the company faced challenges from decreased sales in certain segments. Overall, Cadre's performance reflects strong demand for its safety products and effective operational execution.
Read more →-CDRE
Feb 20, 2024Acquisition Overview: Alpha Safety February 2024 T OGETHER , W E S AVE L IVES 2 FORWARD - LOOKING STATEMENTS Please note that in this presentation Cadre Holdings, Inc. (the "Company" or "Cadre") may use words such as "ap
Cadre Holdings, Inc. is proposing an acquisition of Alpha Safety, which specializes in engineered products for the nuclear industry. This acquisition presents an opportunity for Cadre to diversify its market and tap into a growing segment with significant long-term contracts and demand. Alpha Safety's strong financial performance and established customer base are highlighted as key benefits of the transaction. However, there are risks involved related to the completion of the acquisition and its integration into Cadre's existing operations.
Read more →-CDRE
Nov 8, 2023Cadre Holdings Reports Third Quarter 2023 Financial Results Increased Quarterly Revenue, Net Income, and Gross Margin Sequentially and Year-Over-Year Second Consecutive Quarter of Record Adjusted EBITDA and Adjusted EBIT
Cadre Holdings reported strong financial results for the third quarter of 2023, with substantial increases in revenue, net income, and gross margins. The company achieved record Adjusted EBITDA for the second consecutive quarter and has raised its full-year guidance for net sales and Adjusted EBITDA based on ongoing demand for its safety products. Driven by strategic execution and market demands, Cadre is well-positioned for continued growth in the public safety sector.
Read more →-CDRE
Aug 8, 2023Cadre Holdings Reports Second Quarter 2023 Financial Results Achieved Revenue, Net Income, Gross Margin and Adjusted EBITDA Growth Achieves Record Quarterly Adjusted EBITDA of $22.8 Million and Adjusted EBITDA Margin of
Cadre Holdings, Inc. reported strong financial results for the second quarter of 2023, showing significant growth in revenue, net income, gross margin, and adjusted EBITDA. The company achieved a record Adjusted EBITDA of $22.8 million, and the net sales for the quarter increased to $121.1 million. Management raised its full-year 2023 net sales and adjusted EBITDA guidance, highlighting ongoing demand for their safety and survivability products. Gross profit margins also improved as Cadre continues to leverage its operating model and enhance market leadership.
Read more →-CDRE
May 9, 2023Cadre Holdings Reports First Quarter 2023 Financial Results Achieved Revenue, Net Income and Adjusted EBITDA Growth; Expanded Gross and Adjusted EBITDA Margins Reaffirms 2023 Full-Year Guidance
Cadre Holdings, Inc. reported strong first quarter results for 2023, with revenue reaching $111.7 million and a net income of $7 million, a significant improvement from a net loss in the prior year. The company experienced a 31% increase in adjusted EBITDA, along with improved profit margins, driven by enhanced demand for safety and survivability equipment. CEO Warren Kanders highlighted sustained demand in key markets and a commitment to strategic growth. Cadre reaffirmed its full-year guidance, citing macro tailwinds supporting public safety budgets.
Read more →-CDRE
Mar 15, 2023Cadre Holdings Reports Fourth Quarter and Full Year 2022 Financial Results Generated Record Full Year Net Sales and Adjusted EBITDA Exceeded Pricing Growth Target Above Inflation in Q4 and Full Year Expects Full Year 202
Cadre Holdings reported significant financial results for Q4 and the full year of 2022, achieving record sales and adjusted EBITDA. The company exceeded its price growth target despite challenges posed by supply chain disruptions and inflation. Looking ahead, Cadre forecasts net sales between $463 million and $493 million for 2023, supported by its strategic focus on targeted mergers and acquisitions. However, while net sales increased, net income declined compared to the prior year, attributed to rising stock-based compensation expenses.
Read more →-CDRE
Nov 10, 2022Cadre Holdings Reports Third Quarter 2022 Financial Results Achieved Net Income and Adjusted EBITDA Growth; Expanded Adjusted EBITDA Margin Exceeded Pricing Growth Target Above Inflation Reaffirms 2022 Full-Year Guidance
Cadre Holdings Reports Third Quarter 2022 Financial Results Achieved Net Income and Adjusted EBITDA Growth; Expanded Adjusted EBITDA Margin Exceeded Pricing Growth Target Above Inflation Reaffirms 2022 Full-Year Guidance JACKSONVILLE, Fla., November 10, 2022 - Cadre Holdings,
Read more →-CDRE
Aug 11, 2022Cadre Holdings Reports Second Quarter 2022 Financial Results Exceeds Pricing Growth Target Above Inflation, Generates Strong Adjusted EBITDA Conversion, and Increases Orders Backlog Further Expands International Presence
Cadre Holdings Reports Second Quarter 2022 Financial Results Exceeds Pricing Growth Target Above Inflation, Generates Strong Adjusted EBITDA Conversion, and Increases Orders Backlog Further Expands International Presence and Focus on High Margin Businesses with Strong Recurring
Read more →-CDRE
Jun 9, 2022Cadre Holdings Announces Pricing of Public Primary and Secondary Offering of Common Stock
Cadre Holdings Announces Pricing of Public Primary and Secondary Offering of Common Stock JACKSONVILLE, Fla., June 9, 2022 - Cadre Holdings, Inc. (NYSE: CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety and survivability equipme
Read more →-CDRE
Jun 7, 2022Cadre Holdings Announces Launch of Public Primary and Secondary Offering of Common Stock
Cadre Holdings Announces Launch of Public Primary and Secondary Offering of Common Stock JACKSONVILLE, Fla., June 7, 2022 - Cadre Holdings, Inc. (NYSE: CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety and survivability equipmen
Read more →-CDRE
May 12, 2022Cadre Holdings Reports First Quarter 2022 Financial Results Completes Second Accretive Acquisition Since IPO with Agreement to Add Leading Supplier of Chemical Illumination Solutions to U.S. and NATO Military Forces Rais
Cadre Holdings Reports First Quarter 2022 Financial Results Completes Second Accretive Acquisition Since IPO with Agreement to Add Leading Supplier of Chemical Illumination Solutions to U.S. and NATO Military Forces Raises Guidance to Full Year 2022 Net Sales of $444.0 to $452.
Read more →-CDRE
Mar 10, 2022Cadre Holdings Reports Fourth Quarter 2021 Financial Results Generated Record Full Year Net Sales and Adjusted EBITDA; Expanded Gross Profit Margin and Adjusted EBITDA Margin Completed Acquisition of Well-Established Eur
Cadre Holdings Reports Fourth Quarter 2021 Financial Results Generated Record Full Year Net Sales and Adjusted EBITDA; Expanded Gross Profit Margin and Adjusted EBITDA Margin Completed Acquisition of Well-Established European Duty Gear Brand to Grow International Presence Expe
Read more →-CDRE
Dec 2, 2021Cadre Holdings Reports Third Quarter 2021 Financial Results Expanded Gross Profit Margin and Adjusted EBITDA Margin Completed Initial Public Offering, Raising Gross Proceeds of $89.7 million; Announced Quarterly Cash Div
Cadre Holdings Reports Third Quarter 2021 Financial Expanded Gross Profit Margin and Adjusted EBITDA Initial Public Offering, Raising Gross Proceeds of $89.7 million; Announced Quarterly Cash Dividend Fla., December 2, 2021 - Cadre Holdings, Inc. (NYSE: CDRE) ("Cadre" or "the
Read more →Competitive Position
How CDRE ranks across every disease it competes inCompetitive Position is a premium feature
See how CDRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial